{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T16:57:13Z","timestamp":1780678633328,"version":"3.54.1"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003252","name":"Lund University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100003252","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Urol Rep"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1007\/s11934-018-0750-y","type":"journal-article","created":{"date-parts":[[2018,2,9]],"date-time":"2018-02-09T03:40:08Z","timestamp":1518147608000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Pharmacotherapy for Nocturia"],"prefix":"10.1007","volume":"19","author":[{"given":"Karl-Erik","family":"Andersson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Van Kerrebroeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,2,9]]},"reference":[{"issue":"Suppl 1","key":"750_CR1","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.1002\/nau.22595","volume":"33","author":"P Kerrebroeck Van","year":"2014","unstructured":"Van Kerrebroeck P, Andersson KE. Terminology, epidemiology, etiology, and pathophysiology of nocturia. Neurourol Urodyn. 2014;33(Suppl 1):S2\u20135. \n                      https:\/\/doi.org\/10.1002\/nau.22595\n                      \n                    .","journal-title":"Neurourol Urodyn"},{"issue":"10","key":"750_CR2","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1038\/nrurol.2016.134","volume":"13","author":"H Dani","year":"2016","unstructured":"Dani H, Esdaille A, Weiss JP. Nocturia: aetiology and treatment in adults. Nat Rev Urol. 2016;13(10):573\u201383. \n                      https:\/\/doi.org\/10.1038\/nrurol.2016.134\n                      \n                    .","journal-title":"Nat Rev Urol"},{"issue":"6","key":"750_CR3","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1016\/j.urology.2015.02.043","volume":"85","author":"SD Marshall","year":"2015","unstructured":"Marshall SD, Raskolnikov D, Blanker MH, Hashim H, Kupelian V, Tikkinen KA, et al. Nocturia: current Levels of Evidence and Recommendations From the International Consultation on Male Lower Urinary Tract Symptoms. Urology. 2015;85(6):1291\u20139. \n                      https:\/\/doi.org\/10.1016\/j.urology.2015.02.043\n                      \n                    .","journal-title":"Urology"},{"issue":"5","key":"750_CR4","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/j.eururo.2017.06.010","volume":"72","author":"VI Sakalis","year":"2017","unstructured":"\u2022\u2022 Sakalis VI, Karavitakis M, Bedretdinova D, Bach T, Bosch JLHR, Gacci M, et al. Medical treatment of nocturia in men with lower urinary tract symptoms: systematic review by the European Association of Urology Guidelines Panel for male lower urinary tract symptoms. Eur Urol. 2017. Comprehensive overview of male nocturia treatment.;72(5):757\u201369. \n                      https:\/\/doi.org\/10.1016\/j.eururo.2017.06.010\n                      \n                    .","journal-title":"Eur Urol"},{"issue":"4","key":"750_CR5","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1097\/MOU.0000000000000287","volume":"26","author":"JT Kurtzman","year":"2016","unstructured":"Kurtzman JT, Bergman AM, Weiss JP. Nocturia in women. Curr Opin Urol. 2016;26(4):315\u201320. \n                      https:\/\/doi.org\/10.1097\/MOU.0000000000000287\n                      \n                    .","journal-title":"Curr Opin Urol"},{"issue":"4","key":"750_CR6","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1002\/nau.20913","volume":"29","author":"PE Kerrebroeck Van","year":"2010","unstructured":"Van Kerrebroeck PE, Dmochowski R, FitzGerald MP, Hashim H, Norgaard JP, Robinson D, et al. Nocturia research: current status and future perspectives. Neurourol Urodyn. 2010;29(4):623\u20138. \n                      https:\/\/doi.org\/10.1002\/nau.20913\n                      \n                    .","journal-title":"Neurourol Urodyn"},{"issue":"6","key":"750_CR7","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1177\/1756287213502116","volume":"5","author":"FM Friedman","year":"2013","unstructured":"Friedman FM, Weiss JP. Desmopressin in the treatment of nocturia: clinical evidence and experience. Ther Adv Urol. 2013;5(6):310\u20137. \n                      https:\/\/doi.org\/10.1177\/1756287213502116\n                      \n                    .","journal-title":"Ther Adv Urol"},{"issue":"3","key":"750_CR8","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/j.juro.2014.03.095","volume":"192","author":"MH Ebell","year":"2014","unstructured":"Ebell MH, Radke T, Gardner J. A systematic review of the efficacy and safety of desmopressin for nocturia in adults. J Urol. 2014;192(3):829\u201335. \n                      https:\/\/doi.org\/10.1016\/j.juro.2014.03.095\n                      \n                    .","journal-title":"J Urol"},{"issue":"4","key":"750_CR9","doi-asserted-by":"publisher","first-page":"206","DOI":"10.5301\/uro.5000141","volume":"82","author":"S Siracusano","year":"2015","unstructured":"Siracusano S, Ciciliato S, Toffoli L, Silvestri T, Casotto D. Desmopressin in adult urological disease: clinical evidences. Urologia. 2015;82(4):206\u201310. \n                      https:\/\/doi.org\/10.5301\/uro.5000141\n                      \n                    .","journal-title":"Urologia"},{"key":"750_CR10","unstructured":"Andersson KE, Cardozo L, Cruz F, Lee K-S, Suhai A, Wein AJ. Pharmacological treatment of urinary incontinence. In: Abrams P, Cardozo L, Wagg A, Wein A, editors. Incontinence. 6th International Consultation on Incontinence, Tokyo, September 2016, pp 805\u2013957. The International Continence Society (ICS)and the International Consultation on Urological Diseases (ICUD); 2017."},{"issue":"Suppl 1","key":"750_CR11","doi-asserted-by":"publisher","first-page":"S19","DOI":"10.1002\/nau.22592","volume":"33","author":"JP Weiss","year":"2014","unstructured":"Weiss JP, Juul KV, Wein AJ. Management of nocturia: the role of antidiuretic pharmacotherapy. Neurourol Urodyn. 2014;33(Suppl 1):S19\u201324. \n                      https:\/\/doi.org\/10.1002\/nau.22592\n                      \n                    .","journal-title":"Neurourol Urodyn"},{"key":"750_CR12","doi-asserted-by":"publisher","unstructured":"Epstein M, Blaivas J, Wein AJ, Weiss JP Nocturia treatment outcomes: analysis of contributory frequency volume chart parameters. Neurourol Urodyn. 2017. \n                      https:\/\/doi.org\/10.1002\/nau.23272\n                      \n                    .","DOI":"10.1002\/nau.23272"},{"issue":"4","key":"750_CR13","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1002\/nau.22243","volume":"31","author":"JP Weiss","year":"2012","unstructured":"Weiss JP, Zinner NR, Klein BM, N\u00f8rgaard JP. Desmopressin orally disintegrating tablet effectively reduces nocturia: results of a randomized, double-blind, placebo-controlled trial. Neurourol Urodyn. 2012;31(4):441\u20137. \n                      https:\/\/doi.org\/10.1002\/nau.22243\n                      \n                    .","journal-title":"Neurourol Urodyn"},{"issue":"5","key":"750_CR14","doi-asserted-by":"publisher","first-page":"F1116","DOI":"10.1152\/ajprenal.00741.2010","volume":"300","author":"KV Juul","year":"2011","unstructured":"Juul KV, Klein BM, Sandstr\u00f6m R, Erichsen L, N\u00f8rgaard JP. Gender difference in antidiuretic response to desmopressin. Am J Physiol Renal Physiol. 2011;300(5):F1116\u201322. \n                      https:\/\/doi.org\/10.1152\/ajprenal.00741.2010\n                      \n                    .","journal-title":"Am J Physiol Renal Physiol"},{"issue":"Suppl 1","key":"750_CR15","doi-asserted-by":"publisher","first-page":"S6","DOI":"10.1002\/nau.22594","volume":"33","author":"JG Verbalis","year":"2014","unstructured":"Verbalis JG. Renal physiology of nocturia. Neurourol Urodyn. 2014;33(Suppl 1):S6\u20139. \n                      https:\/\/doi.org\/10.1002\/nau.22594\n                      \n                    .","journal-title":"Neurourol Urodyn"},{"issue":"3","key":"750_CR16","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1016\/j.juro.2012.12.112","volume":"190","author":"JP Weiss","year":"2013","unstructured":"Weiss JP, Herschorn S, Albei CD, van der Meulen EA. Efficacy and safety of low dose desmopressin orally disintegrating tablet in men with nocturia: results of a multicenter, randomized, double-blind, placebo controlled, parallel group study. J Urol. 2013;190(3):965\u201372. \n                      https:\/\/doi.org\/10.1016\/j.juro.2012.12.112\n                      \n                    .","journal-title":"J Urol"},{"issue":"3","key":"750_CR17","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1016\/j.juro.2013.02.037","volume":"190","author":"PK Sand","year":"2013","unstructured":"Sand PK, Dmochowski RR, Reddy J, van der Meulen EA. Efficacy and safety of low dose desmopressin orally disintegrating tablet in women with nocturia: results of a multicenter, randomized, double-blind, placebo controlled, parallel group study. J Urol. 2013;190(3):958\u201364. \n                      https:\/\/doi.org\/10.1016\/j.juro.2013.02.037\n                      \n                    .","journal-title":"J Urol"},{"issue":"2","key":"750_CR18","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1002\/nau.20168","volume":"25","author":"A Rembratt","year":"2006","unstructured":"Rembratt A, Riis A, Norgaard JP. Desmopressin treatment in nocturia; an analysis of risk factors for hyponatremia. Neurourol Urodyn. 2006;25(2):105\u20139. \n                      https:\/\/doi.org\/10.1002\/nau.20168\n                      \n                    .","journal-title":"Neurourol Urodyn"},{"issue":"3","key":"750_CR19","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1159\/000381562","volume":"41","author":"EY Choi","year":"2015","unstructured":"Choi EY, Park JS, Kim YT, Park SY, Kim GH. The risk of hyponatremia with desmopressin use for nocturnal polyuria. Am J Nephrol. 2015;41(3):183\u201390. \n                      https:\/\/doi.org\/10.1159\/000381562\n                      \n                    .","journal-title":"Am J Nephrol"},{"issue":"5","key":"750_CR20","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1111\/bju.13718","volume":"119","author":"KV Juul","year":"2017","unstructured":"Juul KV, Malmberg A, van der Meulen E, Walle JV, N\u00f8rgaard JP. Low-dose desmopressin combined with serum sodium monitoring can prevent clinically significant hyponatraemia in patients treated for nocturia. BJU Int. 2017;119(5):776\u201384. \n                      https:\/\/doi.org\/10.1111\/bju.13718\n                      \n                    .","journal-title":"BJU Int"},{"key":"750_CR21","unstructured":"McElwaine-Johnn H, Schutz R, Yea C, Leese P.The antidiuretic effect of fedovapagon can be effectively controlled by dose. Abstract ICS Florence. 2017."},{"issue":"2","key":"750_CR22","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1111\/j.1464-410X.1988.tb04294.x","volume":"62","author":"PA Pedersen","year":"1988","unstructured":"Pedersen PA, Johansen B. Prophylactic treatment of adult nocturia with bumetanide. Br J Urol. 1988;62(2):145\u20137. \n                      https:\/\/doi.org\/10.1111\/j.1464-410X.1988.tb04294.x\n                      \n                    .","journal-title":"Br J Urol"},{"issue":"2","key":"750_CR23","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1046\/j.1464-410X.1998.00511.x","volume":"81","author":"JM Reynard","year":"1998","unstructured":"Reynard JM, Cannon A, Yang Q, Abrams P. A novel therapy for nocturnal polyuria: a double-blind randomized trial of frusemide against placebo. Br J Urol. 1998;81(2):215\u20138. \n                      https:\/\/doi.org\/10.1046\/j.1464-410X.1998.00511.x\n                      \n                    .","journal-title":"Br J Urol"},{"key":"750_CR24","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1002\/nau.20986","volume":"30","author":"FG Fu","year":"2011","unstructured":"Fu FG, Lavery HJ, Wu DL. Reducing nocturia in the elderly: a randomized placebo-controlled trial of staggered furosemide and desmopressin. Neurourol Urodyn. 2011;30:437\u201352.","journal-title":"Neurourol Urodyn"},{"issue":"1","key":"750_CR25","first-page":"13","volume":"72","author":"\u0141 Dobrek","year":"2015","unstructured":"Dobrek \u0141, Thor PJ. The role of prostanoids in the urinary bladder function and a potential use of prostanoid-targeting pharmacological agents in bladder overactivity treatment. Acta Pol Pharm. 2015;72(1):13\u20139.","journal-title":"Acta Pol Pharm"},{"issue":"4","key":"750_CR26","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1016\/j.eururo.2005.11.026","volume":"49","author":"SK Addla","year":"2006","unstructured":"Addla SK, Adeyoju AB, Neilson D, O\u2019Reilly P. Diclofenac for treatment of nocturia caused by nocturnal polyuria: a prospective, randomised, double-blind, placebo-controlled crossover study. Eur Urol. 2006;49(4):720\u20135. \n                      https:\/\/doi.org\/10.1016\/j.eururo.2005.11.026\n                      \n                    .","journal-title":"Eur Urol"},{"issue":"4","key":"750_CR27","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1016\/j.urology.2008.04.069","volume":"72","author":"S Falahatkar","year":"2008","unstructured":"Falahatkar S, Mokhtari G, Pourreza F, Asgari SA, Kamran AN. Celecoxib for treatment of nocturia caused by benign prostatic hyperplasia: a prospective, randomized, double-blind, placebocontrolled study. Urology. 2008;72(4):813\u20136. \n                      https:\/\/doi.org\/10.1016\/j.urology.2008.04.069\n                      \n                    .","journal-title":"Urology"},{"issue":"5","key":"750_CR28","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1590\/S1677-5538.IBJU.2013.05.07","volume":"39","author":"SN Gorgel","year":"2013","unstructured":"Gorgel SN, Sefik E, Kose O, Olgunelma V, Sahin E. The effect of combined therapy with tamsulosin hydrochloride and meloxicam in patients with benign prostatic hyperplasia symptoms and impact on nocturia and sleep quality. Int Braz J Urol. 2013;39(5):657\u201362. \n                      https:\/\/doi.org\/10.1590\/S1677-5538.IBJU.2013.05.07\n                      \n                    .","journal-title":"Int Braz J Urol"},{"issue":"12","key":"750_CR29","doi-asserted-by":"publisher","first-page":"2110","DOI":"10.1007\/s12325-016-0423-5","volume":"33","author":"CG Roehrborn","year":"2017","unstructured":"Roehrborn CG, Cruz F, Fusco F. \u03b11-Blockers in men with lower urinary tract symptoms suggestive of benign prostatic obstruction: is silodosin different? Adv Ther. 2017;33(12):2110\u201321. \n                      https:\/\/doi.org\/10.1007\/s12325-016-0423-5\n                      \n                    .","journal-title":"Adv Ther"},{"issue":"7","key":"750_CR30","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1038\/ncpuro0836","volume":"4","author":"KE Andersson","year":"2007","unstructured":"Andersson KE, Gratzke C. Pharmacology of alpha1-adrenoceptor antagonists in the lower urinary tract and central nervous system. Nat Clin Pract Urol. 2007;4(7):368\u201378. \n                      https:\/\/doi.org\/10.1038\/ncpuro0836\n                      \n                    .","journal-title":"Nat Clin Pract Urol"},{"issue":"3","key":"750_CR31","doi-asserted-by":"publisher","first-page":"190","DOI":"10.5213\/inj.2015.19.3.190","volume":"19","author":"YW Kim","year":"2015","unstructured":"Kim YW, Park J, Chung H, Kim HW, Kim HJ, Jung JH, et al. The effectiveness of silodosin for nocturnal polyuria in elderly men with benign prostatic hyperplasia: a multicenter study. Int Neurourol J. 2015;19(3):190\u20136. \n                      https:\/\/doi.org\/10.5213\/inj.2015.19.3.190\n                      \n                    .","journal-title":"Int Neurourol J"},{"issue":"1","key":"750_CR32","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.prnil.2015.12.002","volume":"4","author":"BH Kim","year":"2016","unstructured":"Kim BH, Kim KH, Ko YH, Song PH, Kim TH, Kim BS. The prostatic urethral angle can predict the response to alpha adrenoceptor antagonist monotherapy for treating nocturia in men with lower urinary tract symptom: a multicenter study. Prostate Int. 2016;4(1):30\u20135. \n                      https:\/\/doi.org\/10.1016\/j.prnil.2015.12.002\n                      \n                    .","journal-title":"Prostate Int"},{"issue":"5","key":"750_CR33","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1007\/s00345-013-1228-7","volume":"32","author":"A Eisenhardt","year":"2014","unstructured":"Eisenhardt A, Schneider T, Cruz F, Oelke M. Consistent and significant improvement of nighttime voiding frequency (nocturia) with silodosin in men with LUTS suggestive of BPH: pooled analysis of three randomized, placebo-controlled, double-blind phase III studies. World J Urol. 2014;32(5):1119\u201325. \n                      https:\/\/doi.org\/10.1007\/s00345-013-1228-7\n                      \n                    .","journal-title":"World J Urol"},{"issue":"3","key":"750_CR34","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1016\/j.eururo.2010.10.046","volume":"59","author":"CR Chapple","year":"2011","unstructured":"Chapple CR, Montorsi F, Tammela TL, Wirth M, Koldewijn E, Fern\u00e1ndez Fern\u00e1ndez E, et al. Silodosin therapy for lower urinary tract symptoms in men with suspected benign prostatic hyperplasia: results of an international, randomized, double-blind, placebo- and active-controlled clinical trial performed in Europe. Eur Urol. 2011;59(3):342\u201352. \n                      https:\/\/doi.org\/10.1016\/j.eururo.2010.10.046\n                      \n                    .","journal-title":"Eur Urol"},{"issue":"3","key":"750_CR35","first-page":"1636","volume":"11","author":"SO Kim","year":"2014","unstructured":"Kim SO, Choi HS, Kwon D. The \u03b11 adrenoceptor antagonist tamsulosin for the treatment of voiding symptoms improves nocturia and sleep quality in women. Urol J. 2014;11(3):1636\u201341.","journal-title":"Urol J"},{"issue":"2","key":"750_CR36","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.eururo.2013.01.018","volume":"64","author":"C F\u00fcllhase","year":"2013","unstructured":"F\u00fcllhase C, Chapple C, Cornu JN, De Nunzio C, Gratzke C, Kaplan SA, et al. Systematic review of combination drug therapy for non-neurogenic male lower urinary tract symptoms. Eur Urol. 2013;64(2):228\u201343. \n                      https:\/\/doi.org\/10.1016\/j.eururo.2013.01.018\n                      \n                    .","journal-title":"Eur Urol"},{"issue":"3","key":"750_CR37","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1016\/j.eururo.2008.11.026","volume":"56","author":"C Chapple","year":"2009","unstructured":"Chapple C, Herschorn S, Abrams P, Sun F, Brodsky M, Guan Z. Tolterodine treatment improves storage symptoms suggestive of overactive bladder in men treated with \u03b1-blockers. Eur Urol. 2009;56(3):534\u201343. \n                      https:\/\/doi.org\/10.1016\/j.eururo.2008.11.026\n                      \n                    .","journal-title":"Eur Urol"},{"issue":"1","key":"750_CR38","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1097\/01.ju.0000069827.09120.79","volume":"170","author":"TM Johnson 2nd","year":"2003","unstructured":"Johnson TM 2nd, Jones K, Williford WO, Kutner MH, Issa MM, Lepor H. Changes in nocturia from medical treatment of benign prostatic hyperplasia: secondary analysis of the Department of Veterans Affairs Cooperative Study Trial. J Urol. 2003;170(1):145\u20138. \n                      https:\/\/doi.org\/10.1097\/01.ju.0000069827.09120.79\n                      \n                    .","journal-title":"J Urol"},{"issue":"5","key":"750_CR39","doi-asserted-by":"publisher","first-page":"2045","DOI":"10.1016\/j.juro.2007.07.013","volume":"178","author":"ITM Johnson","year":"2007","unstructured":"Johnson ITM, Burrows PK, Kusek JW, et al. The effect of doxazosin, finasteride and combination therapy on nocturia in men with benign prostatic hyperplasia. J Urol. 2007;178(5):2045\u201351. \n                      https:\/\/doi.org\/10.1016\/j.juro.2007.07.013\n                      \n                    .","journal-title":"J Urol"},{"issue":"5","key":"750_CR40","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1007\/s00345-014-1316-3","volume":"32","author":"M Oelke","year":"2014","unstructured":"Oelke M, Roehrborn CG, D\u2019Ancona C, Wilson TH, Castro R, Manyak M. Impact of dutasteride on nocturia in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS\/BPH): a pooled analysis of three phase III studies. World J Urol. 2014;32(5):1141\u20137. \n                      https:\/\/doi.org\/10.1007\/s00345-014-1316-3\n                      \n                    .","journal-title":"World J Urol"},{"issue":"5","key":"750_CR41","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1007\/s00345-014-1296-3","volume":"32","author":"M Oelke","year":"2014","unstructured":"Oelke M, Roehrborn CG, D\u2019Ancona C, Wilson TH, Castro R, Manyak M. Nocturia improvement in the combination of Avodart(\u00ae) and tamsulosin (CombAT) study. World J Urol. 2014;32(5):1133\u201340. \n                      https:\/\/doi.org\/10.1007\/s00345-014-1296-3\n                      \n                    .","journal-title":"World J Urol"},{"issue":"4","key":"750_CR42","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1016\/j.urology.2005.10.061","volume":"67","author":"R Rackley","year":"2006","unstructured":"Rackley R, Weiss JP, Rovner ES, Wang JT, Guan Z, STUDY GROUP. Nighttime dosing with tolterodine reduces overactive bladder-related nocturnal micturitions in patients with overactive bladder and nocturia. Urology. 2006;67(4):731\u20136. \n                      https:\/\/doi.org\/10.1016\/j.urology.2005.10.061\n                      \n                    .","journal-title":"Urology"},{"issue":"4","key":"750_CR43","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1016\/j.juro.2012.11.067","volume":"189","author":"JP Weiss","year":"2013","unstructured":"Weiss JP, Jumadilova Z, Johnson TM 2nd, Fitzgerald MP, Carlsson M, Martire DL, et al. Efficacy and safety of flexible dose fesoterodine in men and women with overactive bladder symptoms including nocturnal urinary urgency. J Urol. 2013;189(4):1396\u2013401. \n                      https:\/\/doi.org\/10.1016\/j.juro.2012.11.067\n                      \n                    .","journal-title":"J Urol"},{"issue":"1","key":"750_CR44","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.juro.2011.02.2700","volume":"186","author":"O Yokoyama","year":"2011","unstructured":"Yokoyama O, Yamaguchi O, Kakizaki H, Itoh N, Yokota T, Okada H, et al. Efficacy of solifenacin on nocturia in Japanese patients with overactive bladder: impact on sleep evaluated by bladder diary. J Urol. 2011;186(1):170\u20134. \n                      https:\/\/doi.org\/10.1016\/j.juro.2011.02.2700\n                      \n                    .","journal-title":"J Urol"},{"issue":"2","key":"750_CR45","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.urology.2005.08.017","volume":"67","author":"D Rudy","year":"2006","unstructured":"Rudy D, Cline K, Harris R, Goldberg K, Dmochowski R. Multicenter phase III trial studying trospium chloride in patients with overactive bladder. Urology. 2006;67(2):275\u201380. \n                      https:\/\/doi.org\/10.1016\/j.urology.2005.08.017\n                      \n                    .","journal-title":"Urology"},{"issue":"6","key":"750_CR46","doi-asserted-by":"publisher","first-page":"2488","DOI":"10.1016\/j.juro.2007.08.033","volume":"178","author":"VW Nitti","year":"2007","unstructured":"Nitti VW, Dmochowski R, Sand PK, Forst HT, Haag-Molkenteller C, Massow U, et al. Efficacy, safety and tolerability of fesoterodine for overactive bladder syndrome. J Urol. 2007;178(6):2488\u201394. \n                      https:\/\/doi.org\/10.1016\/j.juro.2007.08.033\n                      \n                    .","journal-title":"J Urol"},{"issue":"1","key":"750_CR47","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.urology.2009.09.018","volume":"75","author":"RR Dmochowski","year":"2010","unstructured":"Dmochowski RR, Peters KM, Morrow JD, Guan Z, Gong J, Sun F, et al. Randomized, double-blind, placebo-controlled trial of flexible-dose fesoterodine in subjects with overactive bladder. Urology. 2010;75(1):62\u20138. \n                      https:\/\/doi.org\/10.1016\/j.urology.2009.09.018\n                      \n                    .","journal-title":"Urology"},{"issue":"1","key":"750_CR48","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1111\/j.1464-410X.2009.09086.x","volume":"105","author":"S Herschorn","year":"2010","unstructured":"Herschorn S, Swift S, Guan Z, Carlsson M, Morrow JD, Brodsky M, et al. Comparison of fesoterodine and tolterodine extended release for the treatment of overactive bladder: a head to head placebo controlled trial. BJU Int. 2010;105(1):58\u201366. \n                      https:\/\/doi.org\/10.1111\/j.1464-410X.2009.09086.x\n                      \n                    .","journal-title":"BJU Int"},{"issue":"3","key":"750_CR49","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1097\/01.ju.0000110442.47593.ea","volume":"171","author":"MJ Drake","year":"2004","unstructured":"Drake MJ, Mills IW, Noble JG. Melatonin pharmacotherapy for nocturia in men with benign prostatic enlargement. J Urol. 2004;171(3):1199\u2013202. \n                      https:\/\/doi.org\/10.1097\/01.ju.0000110442.47593.ea\n                      \n                    .","journal-title":"J Urol"},{"issue":"5","key":"750_CR50","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1177\/147323000703500513","volume":"35","author":"K Sugaya","year":"2007","unstructured":"Sugaya K, Nishijima S, Miyazato M, Kadekawa K, Ogawa Y. Effects of melatonin and rilmazafone on nocturia in the elderly. J Int Med Res. 2007;35(5):685\u201391. \n                      https:\/\/doi.org\/10.1177\/147323000703500513\n                      \n                    .","journal-title":"J Int Med Res"},{"issue":"1","key":"750_CR51","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s12883-017-0845-y","volume":"17","author":"D Delgado","year":"2017","unstructured":"Delgado D, Canham L, Cotterill N, Cottrell D, Drake MJ, Inglis K, et al. Protocol for a randomized, double blind, placebo controlled, crossover trial of melatonin for treatment of nocturia in adults with multiple sclerosis (MeNiMS). BMC Neurol. 2017;17(1):63. \n                      https:\/\/doi.org\/10.1186\/s12883-017-0845-y\n                      \n                    .","journal-title":"BMC Neurol"},{"issue":"9","key":"750_CR52","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1007\/s00192-013-2042-x","volume":"24","author":"CR Chapple","year":"2013","unstructured":"Chapple CR, Dvorak V, Radziszewski P, Van Kerrebroeck P, Wyndaele JJ, Bosman B, et al. A phase II dose-ranging study of mirabegron in patients with overactive bladder. Int Urogynecol J. 2013;24(9):1447\u201358. \n                      https:\/\/doi.org\/10.1007\/s00192-013-2042-x\n                      \n                    .","journal-title":"Int Urogynecol J"},{"issue":"5","key":"750_CR53","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1007\/s00345-014-1255-z","volume":"32","author":"M Oelke","year":"2014","unstructured":"Oelke M, Weiss JP, Mamoulakis C, Cox D, Ruff D, Viktrup L. Effects of tadalafil on nighttime voiding (nocturia) in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a post hoc analysis of pooled data from four randomized, placebo-controlled clinical studies. World J Urol. 2014;32(5):1127\u201332. \n                      https:\/\/doi.org\/10.1007\/s00345-014-1255-z\n                      \n                    .","journal-title":"World J Urol"},{"key":"750_CR54","doi-asserted-by":"publisher","unstructured":"\u2022 Rovner ES, Raymond K, Andruczyk E, Juul KV. Low-dose desmopressin and tolterodine combination therapy for treating nocturia in women with overactive bladder: a double-blind, randomized, controlled study. Low Urin Tract Symptoms. 2017. \n                      https:\/\/doi.org\/10.1111\/luts.12169\n                      \n                    . Low-dose desmopressin could be safely combined with tolterodine.","DOI":"10.1111\/luts.12169"},{"issue":"2","key":"750_CR55","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/j.juro.2016.08.116","volume":"197","author":"JC Kim","year":"2017","unstructured":"\u2022 Kim JC, Cho KJ, Lee JG, Seo JT, Kim DY, Oh SJ, et al. Efficacy and safety of desmopressin add-on therapy for men with persistent nocturia on \u03b1-blocker monotherapy for lower urinary tract symptoms: a randomized, double-blind, placebo controlled study. J Urol. 2017;197(2):459\u201364. Desmopressin add-on in men with persistent nocturia on \u03b1-blocker was effective and well tolerated. \n                      https:\/\/doi.org\/10.1016\/j.juro.2016.08.116\n                      \n                    .","journal-title":"J Urol"},{"issue":"1","key":"750_CR56","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1080\/17843286.2016.1177276","volume":"72","author":"MA Denys","year":"2017","unstructured":"Denys MA, Bruneel E, Van Laecke S, N\u00f8rgaard JP, Everaert K. Pitfalls and opportunities in multidisciplinary research about nocturia in adults. Acta Clin Belg. 2017;72(1):2\u20135. \n                      https:\/\/doi.org\/10.1080\/17843286.2016.1177276\n                      \n                    .","journal-title":"Acta Clin Belg"}],"container-title":["Current Urology Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11934-018-0750-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11934-018-0750-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11934-018-0750-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,2,8]],"date-time":"2019-02-08T21:36:50Z","timestamp":1549661810000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11934-018-0750-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1]]},"references-count":56,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,1]]}},"alternative-id":["750"],"URL":"https:\/\/doi.org\/10.1007\/s11934-018-0750-y","relation":{},"ISSN":["1527-2737","1534-6285"],"issn-type":[{"value":"1527-2737","type":"print"},{"value":"1534-6285","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1]]},"assertion":[{"value":"9 February 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"K-E Andersson declares no potential conflicts of interest.Philip Van Kerrebroeck is the speaker for Astellas, Astra-Zeneca, Axonics, Blue-Wind, Ferring, and Medtronic","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}],"article-number":"8"}}